/PARD

PARD Stock - Poniard Pharmaceuticals, Inc.

Q: What is the analyst price target for PARD?

Analyst price target information is not currently available for PARD.

Q: What is PARD's market cap?

Market capitalization information is not currently available for PARD.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PARD

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2006

FY2007

FY2008

FY2009

FY2010

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-36.63

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2010	FY2009	FY2008	FY2007	FY2006
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-27,958,000	$-42,978,000	$-49,157,000	$-35,353,000	$-21,234,000
Net Income	$-30,051,000	$-45,715,000	$-48,565,000	$-32,782,000	$-23,294,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-26.40	$-52.40	$-56.40	$-43.20	$-54.80

Company Overview

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.

Visit Website

Earnings History & Surprises

PARD

Beat Rate

65%

Last 20 quarters

Avg Surprise

+6.8%

EPS vs Estimate

Beats / Misses

13/5

2 met exactly

Latest EPS

$-4.40

Q1 2011

EPS Surprise History

Q4 08

+2.7%

$-14.40vs$-14.80

Q2 09

-0.5%

$-15.20vs$-15.13

Q3 09

+18.4%

$-11.20vs$-13.72

Q4 09

+1.1%

$-11.60vs$-11.73

Q2 10

-26.6%

$-11.60vs$-9.16

Q3 10

+28.8%

$-5.60vs$-7.86

Q4 10

+21.1%

$-5.20vs$-6.59

Q1 11

+12.0%

$-4.40vs$-5.00

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2011	Mar 30, 2011	$-5.00	$-4.40	+12.0%	✓ BEAT
Q4 2010	Nov 9, 2010	$-6.59	$-5.20	+21.1%	✓ BEAT
Q3 2010	Aug 9, 2010	$-7.86	$-5.60	+28.8%	✓ BEAT
Q2 2010	May 10, 2010	$-9.16	$-11.60	-26.6%	✗ MISS
Q4 2009	Nov 3, 2009	$-11.73	$-11.60	+1.1%	✓ BEAT
Q3 2009	Aug 4, 2009	$-13.72	$-11.20	+18.4%	✓ BEAT
Q2 2009	May 5, 2009	$-15.13	$-15.20	-0.5%	✗ MISS
Q4 2008	Oct 30, 2008	$-14.80	$-14.40	+2.7%	✓ BEAT
Q3 2008	Jul 31, 2008	$-12.50	$-14.40	-15.2%	✗ MISS
Q2 2008	May 6, 2008	$-12.91	$-11.60	+10.1%	✓ BEAT
Q4 2007	Nov 1, 2007	$-11.49	$-8.00	+30.4%	✓ BEAT
Q3 2007	Aug 7, 2007	$-11.83	$-11.20	+5.3%	✓ BEAT
Q2 2007	May 10, 2007	$-13.72	$-13.60	+0.9%	✓ BEAT
Q3 2004	Aug 3, 2004	$-36.00	$-38.40	-6.7%	✗ MISS
Q2 2003	May 6, 2003	$-38.40	$-38.40	0.0%	= MET
Q4 2002	Nov 13, 2002	$-67.20	$-52.80	+21.4%	✓ BEAT
Q3 2002	Jul 24, 2002	$-67.20	$-67.20	0.0%	= MET
Q1 2002	Feb 8, 2002	$-81.60	$-67.20	+17.6%	✓ BEAT
Q4 2001	Oct 19, 2001	$-67.20	$-69.60	-3.6%	✗ MISS
Q3 2001	Jul 20, 2001	$-64.80	$-52.80	+18.5%	✓ BEAT

Frequently Asked Questions about PARD

What is PARD's current stock price?

Poniard Pharmaceuticals, Inc. (PARD) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for PARD?

No analyst price targets are currently available for this stock.

What sector is Poniard Pharmaceuticals, Inc. in?

Poniard Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is PARD's market cap?

Poniard Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does PARD pay dividends?

No, Poniard Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.